Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

Thiéblemont, Catherine; Tilly, Hervé; Gomes da Silva, María; Casasnovas, Olivier; Fruchart, Christophe; Morschhauser, Franck; Haïoun, Corinne; Lazarovici, Julien; Grosicka, Anida; Perrot, Aurore; Trotman, Judith; Sebban, Catherine; Caballero, Dolores; Greil, Richard; Van Eygen, Koen; Cohen, Amos; González, Hugo; Bouabdallah, Réda; Obéric, Lucie; Corront, Bernadette; Choufi, Bachra; López‐Guillermo, Armando; Catalano, John; Van Hoof, Achiel; Brière, Josette; Cabeçadas, José; Salles, Gilles; Gaulard, Philippe; Bosly, André; Coiffier, Bertrand

doi:10.1200/jco.2017.72.6984

Public

Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

Published in Journal of Clinical Oncology • Apr 20, 2017

Authors:

Catherine Thiéblemont

Hervé Tilly

María Gomes da Silva

Abstract

Purpose The standard treatment of patients with diffuse large B-cell lymphoma (DLBCL) is rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Lenalidomide, an immunomodulatory agent, has shown activity in DLBCL. This randomized phase III trial compared l...

Subject

Medicine

Lenalidomide

Hazard ratio

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!